Biologic disease-modifying antirheumatic drugs in the treatment of major monogenic autoinflammatory diseases: literature review and clinical observation
https://doi.org/10.14412/1996-7012-2021-6-95-100
Abstract
Autoinflammatory diseases (AIDs) are a heterogeneous group of rare genetically determined conditions, the main manifestations of which are episodes of fever in combination with other signs of systemic inflammation: skin rashes, musculoskeletal and neurological disorders, damage to the organs of vision, hearing, etc., as well as acute phase markers and the absence of autoantibodies. The use of biological therapy, especially inhibitors of interleukin 1 (iIL1), in most common monogenic AIDs (mAID) – FMF, TRAPS, HIDS/MKD, CAPS – has shown its high efficiency and led to significant progress in the treatment of these patients. Currently, iIL1 are the first-line drugs for mAIDs therapy, primarily CAPS. In the case of their ineffectiveness or intolerance in certain situations, other biologic disease-modifying antirheumatic drugs can also be used – inhibitors of tumor necrosis factor α and iIL6, but this issue needs further investigation. The article describes a patient with mAID, in whom the diagnosis was made more than 40 years after the onset; administration of targeted therapy even in the late stages of the disease led to a significant improvement in many symptoms and quality of life.
About the Authors
S. O. Salugina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
E. S. Fedorov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
References
1. Fietta P. Autoinflammatory disease: the hereditary periodic fever syndromes. Acta Biomed. 2004 Aug;75(2):92-9.
2. Kuz'mina NN, Salugina SO, Fedorov ES. Autovospalitel'nye zabolevaniya i sindromy u detei [Auto-inflammatory diseases and syndromes in children]. Moscow: IMA-PRESS; 2012. 104 p..
3. Gattorno M. Auto-inflammatory diseases in children. Voprosy sovremennoi pediatrii. 2014; 13(2):55-64. (In Russ.).
4. Hashkes PJ, Laxer RM, Simon A. Textbook of autoinflammation. Springer; 2019.
5. Hansman S, Lainka E, Horneff G, et al. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/ HIDS: a German PRO-KIND initiative. Pediatr Rheumatol Online J. 2020 Feb 17; 18(1):17. doi: 10.1186/s12969-020-0409-3.
6. Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care Res (Hoboken). 2017 Apr;69(4):578-86. doi: 10.1002/acr.23120. Epub 2017 Mar 3.
7. Mukhin NA, Kozlovskaya LV, Rameev VV, et al. Faktory riska razvitiya amiloidoza pri periodicheskoi bolezni. Klinicheskaya farmakologiya i terapiya. 2014;23(5):40-4. (In Russ.).
8. Fedorov ES, Salugina SO. Familial Mediterranean fever (periodic disease): history or a real problem. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(3):61-9. (In Russ.). doi: 10.14412/1996-7012-2018-3-61-69
9. Bachetti T, Ceccherini I. Tumor necrosis factor receptor-associated periodic syndrome as a model linking autophagy and inflammation in protein aggregation diseases. J Mol Med (Berl). 2014 Jun;92(6):583-94. doi: 10.1007/s00109-014-1150-5. Epub 2014 Apr 6.
10. Gattorno M, Obici L, Meini A, et al. Efficacy and safety of Canakinumab in patients with TNF receptor associated periodic syndrome. Arthritis Rheum. 2012 Jan; 64(1):321-2; author reply 322-3. doi: 10.1002/art.33397.
11. Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/ EUROTRAPS international registry. Ann Rheum Dis. 2014 Dec;73(12):2160-7. doi: 10.1136/annrheumdis-2013-204184. Epub 2013 Aug 21.
12. Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015 Sep;74(9):1636-44. doi: 10.1136/annrheumdis-2015-207546. Epub 2015 Jun 24.
13. Ter Haar N, Lachmann H, Ozen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013 May; 72(5):678-85. doi: 10.1136/annrheumdis2011-201268. Epub 2012 Jun 29.
14. Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018 May 17;378(20):1908-19. doi: 10.1056/NEJMoa1706314.
15. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644-51. doi: 10.1136/annrheumdis-2015-208690. Epub 2016 Jan 22.
16. Soriano A, Soriano M, Espinosa G, et al. Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. Front Immunol. 2020 Jun 3;11:865. doi: 10.3389/fimmu.2020.00865. eCollection 2020.
17. Lachmann H, Kone-Paut I, KuemmerleDeschner GB, et al. Use for the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009 Jun 4;360(23):2416-25. doi: 10.1056/NEJMoa0810787.
18. Kuemmerle-Deschner JB, Hachulla E, Gartwright R, et al. Two year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of Canakinumab in pts with cryopyrin associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011 Dec;70(12):2095-102. doi: 10.1136/ard.2011.152728. Epub 2011 Aug 21.
19. Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Sustained remission of symptoms and improved healthrelated quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011;13(6):R202. doi: 10.1186/ar3535. Epub 2011 Dec 9.
20. Goldbach-Mansky R, Sibley C, Felix S, et al. Efficacy and safety of canakinumab in patients with NOMID/CINCA. Ann Rheum Dis. 2012;71(suppl. 3):291.
21. Toker O, Hashkes PJ. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biologics. 2010 May 25;4: 131-8. doi: 10.2147/btt.s7580.
22. Caorsi R, Lepore L, Zulian F, et al. The schedule of administration of Canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther. 2013 Feb 26;15(1):R33. doi: 10.1186/ar4184.
23. Imagawa T, Nishikomori R, Takada H. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol. Mar-Apr 2013;31(2):302-9. Epub 2013 Feb 1.
24. Kuemmerle-Deschner J, Haug I. Canakinumab in patients with cryopyrinassociated periodic syndrome: an update for clinicians. Ther Adv Musculoskelet Dis. 2013 Dec;5(6):315-29. doi: 10.1177/1759720X13502629.
25. Kuemmerle-Deschner JB, Hofer F, Endres T, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology (Oxford). 2016 Apr;55(4):689-96. doi: 10.1093/rheumatology/kev416. Epub 2015 Dec 14.
26. Salugina SO, Fedorov ES, Kuz'mina NN, Zakharova EYu. The interleukin 1 inhibitor canakinumab in the treatment of cryopyrinassociated periodic syndromes (CAPS): clinical experience. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;8(4): 17-24. (In Russ.). doi: 10.14412/1996-7012-2014-4-17-24
27. Walker UA, Tilson HH, Hawkins PN, et al. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registy. RMD Open. 2021 May;7(2):e001663. doi: 10.1136/rmdopen-2021-001663.
28. Gentileschi S, Rigante D, Vitale A, et al. Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term followup and review of the literature. Clin Rheumatol. 2017 Jul;36(7):1687-90. doi: 10.1007/s10067-017-3688-4. Epub 2017 May 23.
29. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition. N Engl J Med. 2006 Aug 10;355(6):581-92. doi: 10.1056/NEJMoa055137.
30. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al Efficacy and Safety of Anakinra Therapy in Pediatric and Adult Patients With the Autoinflammatory MuckleWells Syndrome. Arthritis Rheum. 2011 Mar;63(3):840-9. doi: 10.1002/art.30149.
31. Sibley CH, Plass N, Snow J, et al. Sustained Response and Prevention of Damage Progression in Patients With Neonatal-Onset Multisystem Inflammatory Disease Treated With Anakinra. Arthritis Rheum. 2012 Jul;64(7):2375-86. doi: 10.1002/art.34409.
32. Kostik MM. The use of anakinra in patients with cryopyrin-associated periodic syndromes and other auto-inflammatory diseases. Voprosy sovremennoi pediatrii. 2016;15(6):576-83. (In Russ.).
33. Van der Hilst J, Moutschen M, Messiaen PE, et al. Efficacy of anti-IL-1 treatment in familial mediterranean fever: a systematic review of the literature. Biologics. 2016 Apr 4;10:75-80. doi: 10.2147/BTT.S102954. eCollection 2016.
34. Babaoglu H, Varan O, Kucuk H, et al. On demand use of anakinra for attacks of familial mediterranean fever (FMF). Clin Rheumatol. 2019 Feb;38(2):577-81. doi: 10.1007/s10067-018-4230-z. Epub 2018 Jul 30.
35. Kehribar DY, Ozgen M. Efficacy of antiinterleukin-1 treatment in colchicine-resistant arthritis in patients with familial Mediterranean fever. Eur J Rheumatol. 2021 Jan;8(1):16-9. doi: 10.5152/eurjrheum.2020.20126. Epub 2020 Sep 18.
36. Hoffman HM, Throne ML, Amar NJ, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012 Oct;34(10):2091-103. doi: 10.1016/j.clinthera.2012.09.009. Epub 2012 Sep 29.
37. Kuemmerle-Deschner J, Gautam R, George A, et al. Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome. RMD Open. 2020 Jul;6(2):e001227. doi: 10.1136/rmdopen-2020-001227.
38. Brogan P, Hofer M, KuemmerleDeschner JB, et al. Efficacy and safety of canakinumab in patients with CAPS aged˂months: results from an open-label, multi-center, Phase III trial. Arthritis Rheumatol. 2015;67:248
39. Rigante D. Tumor necrosis factor inhibitors in tumor necrosis factor receptorassociated periodic syndrome: still a chance to work? Intern Emerg Med. 2017 Mar;12(2): 269-70. doi: 10.1007/s11739-016-1570-z. Epub 2016 Nov 5.
40. De Benedetti F, Frenkel J, Calvo I, et al. Efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency and TNF receptor-associated periodic syndrome: 40 week results from the pivotal phase 3 umbrella cluster trial. Arthritis Rheum. 2016; 68:4369-71.
41. Kuemmerle-Deschner JB, Lohse P, Koetter I, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome: description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther. 2011; 13(6):R196. doi: 10.1186/ar3526. Epub 2011 Dec 6.
42. Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, et al. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther. 2013;15(3):R64. doi: 10.1186/ar4237.
43. Parker T, Keddie S, Kidd D, et al. Neurology of the cryopyrin-associated periodic fever syndrome. Eur J Neurol. 2016 Jul; 23(7):1145-51. doi: 10.1111/ene.12965. Epub 2016 Mar 2.
44. Sakalloglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol. Jul-Aug 2006; 24(4):435-7.
45. Daysal LS, Akcil G, Goker B, et al. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum. 2005 Feb 15;53(1):146-7. doi: 10.1002/art.20920.
46. Batu ED, Arici ZS, Bilinger E, Ozen S. Current therapeutic opinion for managing familial Mediterranean fever. Exp Opin Orphan Drug. 2015;3(9):1063-73.
Review
For citations:
Salugina SO, Fedorov ES. Biologic disease-modifying antirheumatic drugs in the treatment of major monogenic autoinflammatory diseases: literature review and clinical observation. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(6):95-100. https://doi.org/10.14412/1996-7012-2021-6-95-100
Views:
784
Email this article 